Verition Fund Management
TPST icon

Verition Fund Management’s Tempest Therapeutics TPST Stock Holding History

Verition Fund Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-205
Closed -$65K – 1393
2020
Q3 		$65K Sell
205
-51
-20% -$17.3K ﹤0.01% 1001
2020
Q2 		$88K Buy
+256
New +$102K ﹤0.01% 1006

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Verition Fund Management's TPST Position: Q4 2020 in Review

Verition Fund Management sold out of Tempest Therapeutics (TPST) in Q4 2020, closing a stake of 205 shares — an estimated $65K sold.

Verition Fund Management first reported a position in TPST in Q2 2020 and held it in 2 quarters. The position peaked at $88K in Q2 2020. 37 funds tracked by Wall St. Rank hold TPST as of Q4 2020.

  • Verition Fund Management reported no remaining Tempest Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Verition Fund Management sold 205 Tempest Therapeutics shares in Q4 2020, an estimated $65K.
  • Verition Fund Management first reported a position in Tempest Therapeutics in Q2 2020 and held it in 2 quarters.
  • Verition Fund Management's Tempest Therapeutics position peaked at $88K in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2020.

Based on Verition Fund Management's 13F filing for Q4 2020, filed 16 Feb 2021.